MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy
ConditionGlioblastoma Multiforme
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Sydney
About this trial
This study is designed to evaluate the role of Oxygen Enhanced (OE) Magnetic resonance imaging (MRI) and Blood Oxygenation Level Dependent (BOLD) MRI in detecting regions of hypoxic tumour and to evaluate their use as imaging methods to selectively deliver targeted radiotherapy to regions of aggressive disease.
Eligibility criteria
Qualifiers
Suspected high-grade glioma (HGG) / glioblastoma multiforme (WHO grade IV) at initial radiological examination
Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2
Available for scanning on two separate days
Disqualifiers
Women lactating, pregnant or of childbearing potential who are not willing to avoid pregnancy during the study
Patients with a history of severe renal disease(s) (eGFR <20) that cannot tolerate gadolinium chelate contrast agents.
Geographically remote patients unable to agree to imaging schedule
Patients who have received anti - vascular endothelial growth factor (anti-VEGF) monoclonal antibody therapy the 3 months prior to recruitment
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
University of Sydney
Lead sponsor
The Brain Cancer Group
Collaborator
Source ClinicalTrials.gov